BofA raised the firm's price target on CME Group to $216 from $209 and keeps a Neutral rating on the shares after the company reported adjusted EPS that beat the firm's estimate and the consensus due to lighter compensation expense. While CME demonstrated its ability to drive volumes against a challenging macroeconomic backdrop with multi-year lows in volatility, soft pricing detracted from the favorable volume result, says the analyst, who also highlights "buyside skepticism" of CME's ability to defend its share in rates futures from BGC's FMX platform.